Antitrust Compliance for China Stocks: New Thresholds for Merger Control Filings

The State Council of the People’s Republic of China published the revised Provisions on Thresholds for Notification of Concentrations of Undertakings (《国务院关于经营者集中申报标准的规定》) on 26 January 2024, effective immediately. This revision, the first since 2008, raised the global and domestic turnover thresholds for mandatory merger control filings by a factor of four, directly impacting the transaction structures of Chinese companies listed on the Hong Kong Exchange (HKEX) and those pursuing dual primary listings in Hong Kong and the United States. For CFOs, company secretaries, and cross-border investment bankers advising on M&A for China-concept stocks, the new thresholds eliminate the mandatory filing requirement for a significant volume of mid-market deals, but simultaneously place greater scrutiny on transactions that meet the revised criteria. The State Administration for Market Regulation (SAMR) now expects filers to demonstrate substantive competition rationale, not merely procedural compliance.

The Revised Filing Thresholds: A Four-Fold Increase

The core change in the 2024 Provisions is the elevation of the revenue-based triggers for mandatory notification. This directly reduces the regulatory burden for smaller acquisitions common in the Chinese technology and consumer sectors, which have historically been the primary constituents of the China-stock universe.

Global and Domestic Turnover Adjustments

Under Article 3 of the 2024 Provisions, a concentration of undertakings must be notified to SAMR if it meets either of two sets of criteria. The first set requires that all participating undertakings in the transaction have a combined global turnover exceeding RMB 12 billion (approximately USD 1.67 billion) in the preceding financial year, and that at least two of the undertakings each have a domestic turnover exceeding RMB 800 million (approximately USD 111 million). The previous threshold, in effect since 2008, was a combined global turnover of RMB 4 billion and individual domestic turnovers of RMB 400 million. This represents a 200% increase in the global turnover threshold and a 100% increase in the domestic turnover threshold.

The second set of criteria, also under Article 3, provides an alternative path to mandatory notification. It requires that all participating undertakings have a combined domestic turnover exceeding RMB 4 billion (previously RMB 2 billion) in the preceding financial year, and that at least two of the undertakings each have a domestic turnover exceeding RMB 800 million. This alternative route captures transactions where the global turnover is below RMB 12 billion but the domestic footprint is substantial. For a Hong Kong-listed company with a market capitalisation of HKD 10 billion and annual revenue of HKD 5 billion, an acquisition of a PRC target with annual revenue of HKD 1 billion would now likely fall below the individual domestic turnover threshold of RMB 800 million, unless the target’s revenue is significantly higher.

Impact on Structuring for China Stocks

The practical effect for China-stock issuers is a material reduction in the number of transactions requiring a SAMR filing. Data from SAMR’s annual reports on merger control enforcement show that in 2022, the agency received 497 notifications and concluded 496 cases. With the threshold increase, SAMR itself has estimated that approximately 30-40% of previously notifiable transactions will no longer require a filing. For a BVI-incorporated, HKEX-listed company with a Cayman Islands holding company, the analysis of whether a filing is required now hinges on the turnover of the target’s PRC operating entity. If that entity’s turnover is below RMB 800 million, and the combined global turnover of the buyer and target is below RMB 12 billion, the transaction can proceed without SAMR clearance, provided no other jurisdictional thresholds are triggered.

SAMR’s Enhanced Review Focus on China-Stock Transactions

While the threshold increase reduces the quantity of filings, the quality of review for transactions that do meet the criteria has intensified. SAMR, through its 2023 Guidelines for the Review of Concentrations of Undertakings (《经营者集中审查规定》), has signalled a shift toward substantive, effects-based analysis, particularly for deals involving digital platforms, data-rich enterprises, and companies with significant market power in the PRC.

Digital Economy and VIE Structures

A critical area of focus for SAMR is the digital economy, which accounts for a disproportionate share of China-stock listings. The 2023 Guidelines explicitly state that SAMR will consider factors such as network effects, data aggregation capabilities, and the ability to restrict or impede market entry when assessing the competitive effects of a concentration. For a US-listed Chinese ADR with a Variable Interest Entity (VIE) structure in the online travel or social media sector, any acquisition of a competitor or a complementary data platform will face heightened scrutiny.

The VIE structure itself introduces a layer of complexity. SAMR’s review is based on the economic substance of the concentration, not the legal form. Even if the transaction is structured as a share purchase of a Cayman Islands holding company, SAMR will look through to the PRC operating entity controlled via the VIE agreements. In a 2022 decision, SAMR imposed conditions on the acquisition of a PRC online recruitment platform by a US-listed competitor, requiring the divestiture of overlapping business lines despite the transaction being structured offshore. The decision, published on SAMR’s official website, cited concerns about data integration and market foreclosure.

Conditional Approvals and Remedies

For transactions that meet the new thresholds and raise competition concerns, SAMR has increasingly resorted to conditional approvals with behavioural remedies rather than outright prohibitions. In 2023, SAMR conditionally approved 5 out of 8 transactions that raised substantive concerns, with the remaining 3 being abandoned by the parties. The remedies typically include commitments to maintain data separation, guarantee interoperability with third-party platforms, and refrain from anti-competitive bundling. For a Hong Kong-listed company in the fintech sector, a conditional approval might require a commitment to keep the acquired entity’s user data separate from the parent’s core banking platform for a period of three years.

Cross-Border Considerations for Dual-Listed Issuers

Companies with dual primary listings in Hong Kong and the United States face a unique set of antitrust compliance challenges, as they must navigate the merger control regimes of multiple jurisdictions simultaneously. The 2024 Provisions do not alter the extraterritorial application of China’s merger control regime; SAMR retains jurisdiction over any concentration that has a potential competitive effect in the PRC market, regardless of where the transaction is consummated.

Coordination with the Committee on Foreign Investment in the United States (CFIUS)

For a company with a primary listing on the Nasdaq and a secondary listing on the HKEX, a cross-border acquisition of a US-based technology firm may trigger both a SAMR filing and a CFIUS review. The two processes operate on different timelines and have different substantive standards. CFIUS focuses on national security risks, while SAMR focuses on competitive effects. In practice, this means that the legal and compliance teams must prepare two separate sets of documentation, often with conflicting requests for information. The 2024 Provisions do not provide for any coordination mechanism between SAMR and foreign regulators, placing the burden entirely on the notifying parties to manage the timeline.

The Role of the HKEX in Antitrust Disclosures

The HKEX’s Listing Rules, specifically Chapter 14 on Notifiable Transactions and Chapter 14A on Connected Transactions, require listed issuers to disclose material regulatory approvals, including antitrust clearances, in their circulars and announcements. For a transaction that requires a SAMR filing, the issuer must include a statement in the circular that the filing has been made and that the transaction is conditional upon receiving SAMR approval. Failure to disclose this condition can result in a breach of the Listing Rules and potential suspension of trading. In 2023, the HKEX issued a guidance letter reminding issuers that the disclosure obligations extend to the risk of a conditional approval with remedies, which must be quantified in the financial impact section of the circular.

Practical Compliance Steps for CFOs and Company Secretaries

The revised thresholds and enhanced SAMR review demand a proactive compliance approach from the boardroom. The following steps are based on current regulatory practice and the 2024 Provisions.

Early Assessment of Filing Obligations

The first step is to establish a clear internal process for assessing whether a proposed transaction triggers a SAMR filing obligation. This requires a detailed review of the target’s audited financial statements for the preceding financial year, with a specific focus on PRC-source revenue. For a private target that does not publish audited accounts, the buyer must rely on management accounts or a vendor due diligence report. The assessment should be conducted at least four weeks before signing the definitive agreement, as the SAMR filing process can take 30 to 90 days for a simple case and up to 180 days for a complex one.

Preparing a Robust Filing Dossier

If a filing is required, the quality of the submission is critical. SAMR’s 2023 Guidelines require a detailed description of the relevant product and geographic markets, the market shares of the parties, and the competitive dynamics of the industry. For a China-stock company with a broad product portfolio, the market definition exercise is often the most contentious part of the filing. The notifying party must present a defensible definition that aligns with SAMR’s precedents in the sector. In the pharmaceutical sector, for example, SAMR has defined relevant markets at the Anatomical Therapeutic Chemical (ATC) classification level 3, which is more granular than the ATC level 1 used by the European Commission.

Monitoring Post-Closing Conditions

For transactions that receive conditional approval, the compliance burden does not end at closing. The remedies imposed by SAMR are legally binding and are subject to monitoring by SAMR’s Enforcement Bureau. The company must appoint an independent monitoring trustee, approved by SAMR, to oversee compliance with the remedies. The trustee’s reports must be submitted to SAMR on a quarterly basis for the duration of the remedy period, which is typically three to five years. Failure to comply with the remedies can result in fines of up to 10% of the company’s annual turnover in the preceding financial year, as per Article 58 of the Anti-Monopoly Law of the People’s Republic of China (《中华人民共和国反垄断法》).

Actionable Takeaways

1. Reassess your deal pipeline: Immediately review all pending and planned M&A transactions for the next 12 months against the new RMB 12 billion global and RMB 800 million individual domestic turnover thresholds; a significant portion of mid-market deals will no longer require a SAMR filing.

2. Document the PRC revenue of every target: For any acquisition target, obtain audited financial statements or certified management accounts showing PRC-source revenue for the preceding financial year, as this is the single most important data point for determining filing obligations.

3. Build a SAMR filing timeline into every transaction agreement: Include a condition precedent in the share purchase agreement that the transaction is subject to SAMR clearance, with a clear long-stop date that accounts for the maximum review period of 180 days.

4. Prepare for remedies in digital economy deals: If your company operates in the digital platform, fintech, or data-intensive sectors, assume that any transaction meeting the new thresholds will attract a Phase 2 review and be prepared to offer behavioural remedies, particularly around data separation and interoperability.

5. Coordinate with your HKEX compliance team: Ensure that the company secretariat updates the standard disclosure templates for notifiable transactions to include a specific section on SAMR filing status and the risk of conditional remedies, as required by HKEX Listing Rules Chapter 14.